Home

Barry J. Simon

CIK 1647994 · See remarks · last filed 2026-06-26

Barry J. Simon is a corporate insider who has filed 39 SEC Form 4 insider transactions across 4 companies since 2015. The most recent filing shows the insider sold $196.9K of IBRX on Jun 26, 2026. Across all open-market trades the lifetime net is −$17.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $22.6M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$22.59M

Companies

4

Total Filings

39

Lifetime Open-Market Net

-$17.52M

Filer Profile

Reported Address
2533 SOUTH COAST HIGHWAY 101
SUITE 210
CARDIFF-BY-THE-SEA, CA 92007
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
IBRX Director 2,802,788 $8.06 $22.59M -$6.16M 14 2026-06-26
Viracta Therapeutics, Inc. (VIRX) Delisted Director — $0.01 — $0 4 2024-06-24
ImmunityBio, Inc. (NK) Delisted See remarks 3,213,783 — — -$11.36M 15 2021-02-08
CUE Director — $30.50 — $0 4 2021-01-06

Recent Filings

39 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-26 IBRX Sell (S) −25,000 -$196.9K EDGAR
2026-06-05 IBRX Sell (S) −23,033 -$165.3K EDGAR
2026-06-04 IBRX Notice (144) −268,033 -$2.95M EDGAR
2026-02-26 IBRX Sell (S) −75,000 -$900.8K EDGAR
2026-02-24 IBRX Mixed −165,783 -$1.84M EDGAR
2026-01-21 IBRX Sell (S) −151,967 -$1.09M EDGAR
2026-01-20 IBRX Notice (144) −571,967 -$5.91M EDGAR
2025-02-25 IBRX Mixed +9,790 -$18.6K EDGAR
2025-01-24 IBRX Exer (M) +110,020 $219.9K EDGAR
2024-06-24 Viracta Therapeutics, Inc. (VIRX) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 39
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.